Supplementation  ||| S:0 E:16 ||| NNP
of  ||| S:16 E:19 ||| IN
L-carnitine  ||| S:19 E:31 ||| JJ
to  ||| S:31 E:34 ||| TO
the  ||| S:34 E:38 ||| DT
severe  ||| S:38 E:45 ||| JJ
motor  ||| S:45 E:51 ||| NN
and  ||| S:51 E:55 ||| CC
intellectual  ||| S:55 E:68 ||| JJ
disabilities  ||| S:68 E:81 ||| NNS
fed  ||| S:81 E:85 ||| VBN
with  ||| S:85 E:90 ||| IN
enteral  ||| S:90 E:98 ||| JJ
carnitine-deficient  ||| S:98 E:118 ||| JJ
formulas  ||| S:118 E:127 ||| NNS
for  ||| S:127 E:131 ||| IN
years  ||| S:131 E:137 ||| NNS
We  ||| S:137 E:140 ||| PRP
clarified  ||| S:140 E:150 ||| VBD
the  ||| S:150 E:154 ||| DT
asymptomatic  ||| S:154 E:167 ||| JJ
deficiency  ||| S:167 E:178 ||| NN
of  ||| S:178 E:181 ||| IN
serum  ||| S:181 E:187 ||| JJ
free-carnitine  ||| S:187 E:202 ||| NN
in  ||| S:202 E:205 ||| IN
the  ||| S:205 E:209 ||| DT
severe  ||| S:209 E:216 ||| JJ
motor  ||| S:216 E:222 ||| NN
and  ||| S:222 E:226 ||| CC
intellectual  ||| S:226 E:239 ||| JJ
disabilities  ||| S:239 E:252 ||| NNS
( ||| S:252 E:253 ||| -LRB-
SMIDs ||| S:253 E:258 ||| NNP
)  ||| S:258 E:260 ||| -RRB-
fed  ||| S:260 E:264 ||| VBN
with  ||| S:264 E:269 ||| IN
enteral  ||| S:269 E:277 ||| JJ
carnitine-deficient  ||| S:277 E:297 ||| JJ
formulas  ||| S:297 E:306 ||| NNS
for  ||| S:306 E:310 ||| IN
years ||| S:310 E:315 ||| NNS
,  ||| S:315 E:317 ||| ,
and  ||| S:317 E:321 ||| CC
investigated  ||| S:321 E:334 ||| VBD
the  ||| S:334 E:338 ||| DT
adequate  ||| S:338 E:347 ||| JJ
method  ||| S:347 E:354 ||| NN
to  ||| S:354 E:357 ||| TO
supply  ||| S:357 E:364 ||| VB
enteral  ||| S:364 E:372 ||| JJ
L-carnitine  ||| S:372 E:384 ||| JJ
and  ||| S:384 E:388 ||| CC
maintain  ||| S:388 E:397 ||| VB
its  ||| S:397 E:401 ||| PRP$
normal  ||| S:401 E:408 ||| JJ
levels ||| S:408 E:414 ||| NNS
.  ||| S:414 E:416 ||| .
In  ||| S:416 E:419 ||| IN
45  ||| S:419 E:422 ||| CD
SMIDs  ||| S:422 E:428 ||| NNS
who  ||| S:428 E:432 ||| WP
has  ||| S:432 E:436 ||| VBZ
been  ||| S:436 E:441 ||| VBN
fed  ||| S:441 E:445 ||| VBN
with  ||| S:445 E:450 ||| IN
carnitine-deficient  ||| S:450 E:470 ||| JJ
formulas  ||| S:470 E:479 ||| NNS
and ||| S:479 E:482 ||| CC
/ ||| S:482 E:483 ||| NNP
or  ||| S:483 E:486 ||| CC
receiving  ||| S:486 E:496 ||| VBG
valproate ||| S:496 E:505 ||| NN
,  ||| S:505 E:507 ||| ,
the  ||| S:507 E:511 ||| DT
serum  ||| S:511 E:517 ||| JJ
free-carnitine  ||| S:517 E:532 ||| JJ
levels  ||| S:532 E:539 ||| NNS
were  ||| S:539 E:544 ||| VBD
examined ||| S:544 E:552 ||| VBN
.  ||| S:552 E:554 ||| .
To  ||| S:554 E:557 ||| TO
the  ||| S:557 E:561 ||| DT
carnitine  ||| S:561 E:571 ||| JJ
deficient  ||| S:571 E:581 ||| JJ
cases  ||| S:581 E:587 ||| NNS
we  ||| S:587 E:590 ||| PRP
introduced  ||| S:590 E:601 ||| VBD
L-carnitine  ||| S:601 E:613 ||| JJ
and ||| S:613 E:616 ||| CC
/ ||| S:616 E:617 ||| NNP
or  ||| S:617 E:620 ||| CC
a  ||| S:620 E:622 ||| DT
carnitine-supplemented  ||| S:622 E:645 ||| JJ
formula  ||| S:645 E:653 ||| NN
to  ||| S:653 E:656 ||| TO
normalize  ||| S:656 E:666 ||| VB
and  ||| S:666 E:670 ||| CC
maintain  ||| S:670 E:679 ||| VB
the  ||| S:679 E:683 ||| DT
serum  ||| S:683 E:689 ||| JJ
free-carnitine  ||| S:689 E:704 ||| JJ
levels ||| S:704 E:710 ||| NNS
.  ||| S:710 E:712 ||| .
Thirty-one  ||| S:712 E:723 ||| JJ
out  ||| S:723 E:727 ||| RP
of  ||| S:727 E:730 ||| IN
34  ||| S:730 E:733 ||| CD
cases  ||| S:733 E:739 ||| NNS
( ||| S:739 E:740 ||| -LRB-
91.2 ||| S:740 E:744 ||| CD
% ||| S:744 E:745 ||| NN
)  ||| S:745 E:747 ||| -RRB-
fed  ||| S:747 E:751 ||| VBN
with  ||| S:751 E:756 ||| IN
carnitine-deficient  ||| S:756 E:776 ||| JJ
formulas  ||| S:776 E:785 ||| NNS
for  ||| S:785 E:789 ||| IN
years  ||| S:789 E:795 ||| NNS
had  ||| S:795 E:799 ||| VBD
serum  ||| S:799 E:805 ||| JJ
free-carnitine  ||| S:805 E:820 ||| JJ
deficiency ||| S:820 E:830 ||| NN
.  ||| S:830 E:832 ||| .
Supplement  ||| S:832 E:843 ||| NN
of  ||| S:843 E:846 ||| IN
15  ||| S:846 E:849 ||| CD
-  ||| S:849 E:851 ||| :
30  ||| S:851 E:854 ||| CD
mg ||| S:854 E:856 ||| CD
/ ||| S:856 E:857 ||| CD
kg ||| S:857 E:859 ||| CD
/ ||| S:859 E:860 ||| CD
day  ||| S:860 E:864 ||| NN
L-carnitine  ||| S:864 E:876 ||| NN
was  ||| S:876 E:880 ||| VBD
effective  ||| S:880 E:890 ||| JJ
to  ||| S:890 E:893 ||| TO
normalize  ||| S:893 E:903 ||| VB
the  ||| S:903 E:907 ||| DT
serum  ||| S:907 E:913 ||| JJ
free-carnitine  ||| S:913 E:928 ||| JJ
levels  ||| S:928 E:935 ||| NNS
within  ||| S:935 E:942 ||| IN
3  ||| S:942 E:944 ||| CD
months ||| S:944 E:950 ||| NNS
.  ||| S:950 E:952 ||| .
After  ||| S:952 E:958 ||| IN
successful  ||| S:958 E:969 ||| JJ
supplementation ||| S:969 E:984 ||| NN
,  ||| S:984 E:986 ||| ,
smaller  ||| S:986 E:994 ||| JJR
dosage  ||| S:994 E:1001 ||| NN
of  ||| S:1001 E:1004 ||| IN
L-carnitine  ||| S:1004 E:1016 ||| NNP
( ||| S:1016 E:1017 ||| -LRB-
100  ||| S:1017 E:1021 ||| CD
or  ||| S:1021 E:1024 ||| CC
300  ||| S:1024 E:1028 ||| CD
mg ||| S:1028 E:1030 ||| CD
/ ||| S:1030 E:1031 ||| CD
day ||| S:1031 E:1034 ||| NN
)  ||| S:1034 E:1036 ||| -RRB-
was  ||| S:1036 E:1040 ||| VBD
enough  ||| S:1040 E:1047 ||| RB
to  ||| S:1047 E:1050 ||| TO
maintain  ||| S:1050 E:1059 ||| VB
the  ||| S:1059 E:1063 ||| DT
normal  ||| S:1063 E:1070 ||| JJ
levels ||| S:1070 E:1076 ||| NNS
.  ||| S:1076 E:1078 ||| .
Replacement  ||| S:1078 E:1090 ||| NN
of  ||| S:1090 E:1093 ||| IN
the  ||| S:1093 E:1097 ||| DT
carnitine-deficient  ||| S:1097 E:1117 ||| JJ
formulas  ||| S:1117 E:1126 ||| NNS
to  ||| S:1126 E:1129 ||| TO
carnitine-supplemented  ||| S:1129 E:1152 ||| JJ
ones  ||| S:1152 E:1157 ||| NNS
was  ||| S:1157 E:1161 ||| VBD
also  ||| S:1161 E:1166 ||| RB
useful  ||| S:1166 E:1173 ||| JJ
to  ||| S:1173 E:1176 ||| TO
normalize  ||| S:1176 E:1186 ||| VB
the  ||| S:1186 E:1190 ||| DT
serum  ||| S:1190 E:1196 ||| JJ
free-carnitine  ||| S:1196 E:1211 ||| JJ
levels ||| S:1211 E:1217 ||| NNS
.  ||| S:1217 E:1219 ||| .
Smaller  ||| S:1219 E:1227 ||| JJR
dosage  ||| S:1227 E:1234 ||| NN
of  ||| S:1234 E:1237 ||| IN
L-carnitine  ||| S:1237 E:1249 ||| JJ
or  ||| S:1249 E:1252 ||| CC
a  ||| S:1252 E:1254 ||| DT
carnitine-supplemented  ||| S:1254 E:1277 ||| JJ
formula  ||| S:1277 E:1285 ||| NN
is  ||| S:1285 E:1288 ||| VBZ
sufficient  ||| S:1288 E:1299 ||| JJ
to  ||| S:1299 E:1302 ||| TO
normalize  ||| S:1302 E:1312 ||| VB
and  ||| S:1312 E:1316 ||| CC
maintain  ||| S:1316 E:1325 ||| VB
the  ||| S:1325 E:1329 ||| DT
serum  ||| S:1329 E:1335 ||| JJ
free-carnitine  ||| S:1335 E:1350 ||| JJ
levels  ||| S:1350 E:1357 ||| NNS
in  ||| S:1357 E:1360 ||| IN
SMIDs  ||| S:1360 E:1366 ||| JJ
fed  ||| S:1366 E:1370 ||| NN
with  ||| S:1370 E:1375 ||| IN
carnitine-deficient  ||| S:1375 E:1395 ||| JJ
formulas  ||| S:1395 E:1404 ||| NNS
for  ||| S:1404 E:1408 ||| IN
years ||| S:1408 E:1413 ||| NNS
.  ||| S:1413 E:1415 ||| .
